The Seattle-based medtech startup Proprio expects the Food and Drug Administration to approve its AR-platform Paradigm in H1 2023.

The Seattle-based medtech startup Proprio expects the Food and Drug Administration to approve its AR-platform Paradigm in H1 2023. 

The six-year-old startup's Paradigm technology can improve surgery outcomes by helping surgeons identify where to insert incisions and place hardware. 

More: 

  • Following its approval, the company plans to commercially launch the program. 
  • Paradigm uses high-def imaging technology to capture the operating room from above. 
    • It then uses AI and augmented reality to combine those images with pre-surgery 3D imaging.
    • These images then guide the doctor through surgery. 
  • Proprio has several technology partners, including Intel, HTC, NVIDIA, Samsung, and the Paul G. Allen School of Computer Science at the University of Washington.

x
x

Post a Comment

Previous Next

Contact Form